Suppr超能文献

分析血浆中的蛋白酶切割模式以检测胰腺癌。

Profiling protease cleavage patterns in plasma for pancreatic cancer detection.

作者信息

Stewart Morgan R, Quentel Arnaud, Manalo Elise, Montoya Mira Jose, Ranganathan Srivathsan, Branchaud Bruce P, Fischer Jared M, Tu Eugene, Civitci Fehmi, Chiu Yu-Jui, Yildirim Adem

机构信息

CEDAR, Knight Cancer Institute, School of Medicine, Oregon Health and Science University, Portland, OR, 97201, USA.

Department of Biomedical Engineering, School of Medicine, Oregon Health and Science University, Portland, OR, 97239, USA.

出版信息

Sci Rep. 2024 Dec 30;14(1):31809. doi: 10.1038/s41598-024-83077-0.

Abstract

Proteases are promising biomarkers for cancer early detection. Their enzymatic activity against peptide substrates allows for their straightforward detection using low-cost tests. However, the complexity of the human proteome makes it challenging to develop sensitive and selective tests against a specific protease biomarker. Here, we report a different approach by utilizing the total protease activity in plasma samples to detect pancreatic cancer. Instead of targeting a specific protease using a specific peptide substrate, we utilized an array of 360 FRET substrates to screen for cleavage patterns in plasma samples collected from screen negatives and pancreatitis or pancreatic ductal adenocarcinoma cancer (PDAC) patients. In this proof of concept study, we first screened all 360 substrates using a small cohort (n = 13) to identify the top 5 substrates that best separate different conditions. Then, we performed a validation study using a larger cohort (n = 86) and the selected substrates. There was a statistically significant increase in the total protease activity in PDAC samples compared to screen negative and pancreatitis samples. The selected substrates detected PDAC with an area under the curve (AUC) of 0.8. This work represents a novel strategy for identifying peptide substrates for the detection of PDAC and other cancers.

摘要

蛋白酶是癌症早期检测中很有前景的生物标志物。它们对肽底物的酶活性使得使用低成本检测方法就能直接检测到它们。然而,人类蛋白质组的复杂性使得开发针对特定蛋白酶生物标志物的灵敏且选择性的检测方法具有挑战性。在此,我们报告一种不同的方法,即利用血浆样本中的总蛋白酶活性来检测胰腺癌。我们没有使用特定的肽底物靶向特定的蛋白酶,而是利用一组360种荧光共振能量转移(FRET)底物来筛选从筛查阴性者以及胰腺炎或胰腺导管腺癌(PDAC)患者采集的血浆样本中的裂解模式。在这项概念验证研究中,我们首先使用一个小队列(n = 13)对所有360种底物进行筛选,以确定最能区分不同情况的前5种底物。然后,我们使用一个更大的队列(n = 86)和所选底物进行了验证研究。与筛查阴性和胰腺炎样本相比,PDAC样本中的总蛋白酶活性有统计学上的显著增加。所选底物检测PDAC的曲线下面积(AUC)为0.8。这项工作代表了一种识别用于检测PDAC和其他癌症的肽底物的新策略。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5679/11686259/00d6b9a4b648/41598_2024_83077_Fig1_HTML.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验